Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Senthil K. Radhakrishnan"'
Autor:
Holly A. Byers, Amy N. Brooks, Janakiram R. Vangala, Jacqueline M. Grible, Alex Feygin, Charles V. Clevenger, J. Chuck Harrell, Senthil K. Radhakrishnan
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Proteasomes are multi-subunit complexes that specialize in protein degradation. Cancer cells exhibit a heightened dependence on proteasome activity, presumably to support their enhanced proliferation and other cancer-related characteristics.
Externí odkaz:
https://doaj.org/article/b82055ba10214bee8c5bbb1360cff8ce
Autor:
Frederick M. Tomlin, Ulla I. M. Gerling-Driessen, Yi-Chang Liu, Ryan A. Flynn, Janakiram R. Vangala, Christian S. Lentz, Sandra Clauder-Muenster, Petra Jakob, William F. Mueller, Diana Ordoñez-Rueda, Malte Paulsen, Naoko Matsui, Deirdre Foley, Agnes Rafalko, Tadashi Suzuki, Matthew Bogyo, Lars M. Steinmetz, Senthil K. Radhakrishnan, Carolyn R. Bertozzi
Publikováno v:
ACS Central Science, Vol 3, Iss 11, Pp 1143-1155 (2017)
Externí odkaz:
https://doaj.org/article/deaad0a3f1e64ba9ac1a503375d3faa2
Autor:
Graeme F. Murray, Tia H. Turner, Daniel Guest, Kevin A. Leslie, Mohammad A. Alzubi, Senthil K. Radhakrishnan, J. Chuck Harrell, Jason Reed
Publikováno v:
Frontiers in Physics, Vol 7 (2019)
The development of resistance to initially successful cancer therapies is a major cause of the morbidity and mortality associated with cancer. Identifying evolving resistance at an early stage could inform clinical decision making to adapt therapies
Externí odkaz:
https://doaj.org/article/f4ce7a986b1045b697a7f7f2889700c6
Publikováno v:
Biomolecules, Vol 10, Iss 4, p 501 (2020)
Currently, proteasome inhibitors bortezomib, carfilzomib, and ixazomib are successfully used in clinics to treat multiple myeloma. However, these agents show limited efficacy against solid tumors. Identification of drugs that can potentiate the actio
Externí odkaz:
https://doaj.org/article/aa7a62b50c45476ba453ce740f8d84e0
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 1, p 327 (2020)
Proteasome inhibition is used therapeutically to induce proteotoxic stress and trigger apoptosis in cancer cells that are highly dependent on the proteasome. As a mechanism of resistance, inhibition of the cellular proteasome induces the synthesis of
Externí odkaz:
https://doaj.org/article/84637958aab0453b80a2df80daaa99bc
Autor:
Andrei L. Gartel, Robert H. Costa, I-Ching Wang, Douglas E. Hughes, Uppoor G. Bhat, Senthil K. Radhakrishnan
Supplementary Figure S1 from Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ad7db230361d8ad70e8ac372dfdd97
https://doi.org/10.1158/0008-5472.22364619
https://doi.org/10.1158/0008-5472.22364619
Autor:
Andrei L. Gartel, Robert H. Costa, I-Ching Wang, Douglas E. Hughes, Uppoor G. Bhat, Senthil K. Radhakrishnan
Supplementary Table S2 from Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fa7e19db4c556ae067d9127b6991649
https://doi.org/10.1158/0008-5472.22364613.v1
https://doi.org/10.1158/0008-5472.22364613.v1
Supplementary Figure 1 from A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e12a72cd4604ecd394b65e9407ece0
https://doi.org/10.1158/0008-5472.22366932.v1
https://doi.org/10.1158/0008-5472.22366932.v1
Autor:
Andrei L. Gartel, Robert H. Costa, I-Ching Wang, Douglas E. Hughes, Uppoor G. Bhat, Senthil K. Radhakrishnan
The oncogenic transcription factor forkhead box M1 (FoxM1) is overexpressed in a number of different carcinomas, whereas its expression is turned off in terminally differentiated cells. For this reason, FoxM1 is an attractive target for therapeutic i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a689e55f2eff364da2c74dc9f44e8c
https://doi.org/10.1158/0008-5472.c.6494283
https://doi.org/10.1158/0008-5472.c.6494283
Using a high-throughput cell-based assay, we identified a nucleoside analogue 4-amino-6-hydrazino-7-β-d-ribofuranosyl-7H-pyrrolo(2,3-d)-pyrimidine-5-carboxamide (ARC), which has the properties of a general transcriptional inhibitor. Specifically, AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d99e03150e5694af81a8a67b9d19c7
https://doi.org/10.1158/0008-5472.c.6495351
https://doi.org/10.1158/0008-5472.c.6495351